Document:

EX-10.6

 Exhibit 10.6 

CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 COLLABORATION AGREEMENT 

This COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of November 23, 2021 (the “Effective
Date”), by and between InveniAI LLC, a wholly owned subsidiary of [***], a Delaware Incorporated located at 2614 Boston Post Road, Suite 33B, Guilford, CT 06437 (“InveniAI”) and Relief Therapeutics Holding SA, a Switzerland
corporation located at Bâtiment F2/F3, Avenue de Sécheron 15, 1202 Genève, Switzerland (“Relief”). 

BACKGROUND 

WHEREAS, Relief is a biopharmaceutical company whose objective is to provide patients with therapeutic RELIEF in serious diseases with
high unmet medical need. They focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific
rationale. This allows them to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Relief is seeking technology enabled artificial intelligence (AI) solution from
InveniAI to generate testable hypotheses and product concepts (repurposing and reformulation candidates) across rare diseases; 

WHEREAS, InveniAI has developed a platform for the identification of potential pharmaceutical product opportunities called Pharma Big
Data Innovation Lab (“Platform”), consisting of (i) its proprietary AlphaMeld® platform, which is a cloud-based Artificial Intelligence platform that utilizes proprietary
machine learning and deep learning based neural networks to identify product opportunities in therapeutic areas, (ii) cross-functional teams at its Integrated Center of Excellence, and (iii) domain expertise, to generate novel
pharmaceutical opportunities and identify potential approaches to development of such concepts; 
 WHEREAS, InveniAI and Relief
desire to initiate a strategic collaboration, wherein InveniAI will use its Platform to help navigate the volume of data for all regulatory agency approved drugs and their associated active ingredients (Active Pharmaceutical Ingredient (API)) and
associate to potential rare disease indications, “API-disease combinations” for IND-enabling, development and commercialization by Relief (“Product
Concepts”). InveniAI will prioritize top Product Concepts, associated diseases, scientific package and evidence to support the hypotheses. 

NOW, THEREFORE, In consideration of the mutual promises and conditions in this Agreement, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
 1. DEFINITIONS 

Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, will have the meanings set forth below,
or the meaning as designated in the indicated places throughout this Agreement. 

 1.1. “AB Rated Product” means a product approved by a regulatory
agency that has determined the product to be bioequivalent to an existing or already-approved product identified as an Approved Product Concept. 

1.2. “Accepted Product Concept” has the meaning ascribed to it in Section 2.5.3. 

1.3. “Additional Product Concepts” has the meaning ascribed to it in Section 2.5.3. 

1.4. “Affiliate” of a Party means any Person that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used in this Section 1.2, “control” will mean (i) direct or indirect beneficial ownership
of at least fifty percent (50%) of the voting share capital or other equity interest in such Person or (ii) the power to direct the management of such Person by contract or otherwise. 

1.5. “Approved Active Pharmaceutical Ingredients (APIs)” has the meaning ascribed to it in the Background to this
Agreement. 
 1.6. “Bankruptcy Laws” means Section 365(n) of Title 11 of the United States Code, the U.S.
Bankruptcy Code and any foreign counterparts thereto. 
 1.7. [***] 

1.8. “Business Day” means any day Monday through Friday, provided that if an activity to be performed or an event to
occur falls on a Friday, Saturday, Sunday or any other day which is recognized as a national holiday in New York, New York or in Genève, Switzerland, then the activity may be performed or the event may occur on the next day that is not a
Friday, Saturday, Sunday or such nationally recognized holiday. 
 1.9. “Commercialization Payment” has the meaning
ascribed to it in Section 5.3. 
 1.10. “Commercially Reasonable Efforts” means, with respect to the efforts to
be expended by a Party pertaining to a particular objective under this Agreement, the efforts and resources commonly used by a similarly situated (with respect to size, stage of development and assets) company for similar products or product
candidates, as applicable, to accomplish a similar objective under similar circumstances exercising reasonable business judgment “Confidential Information” means any confidential or proprietary information or data disclosed by either Party
or its Affiliates or Representatives under this Agreement, whether provided in written, oral, graphic, visual, electronic or other form, including any non-public information relating to the Product Concepts,
the Development Program, development efforts, new inventions, sources of materials, cost, pricing and other financial information, and IP Rights and Patent information, in each case that is marked or otherwise identified as proprietary or
confidential at the time of disclosure, or that the receiving Party should reasonably know to be confidential or proprietary. 

1.11. “Control” or “Controlled” means, with respect to any IP Rights, the possession (whether by
ownership, license, sublicense or contract, other than pursuant to this Agreement) by a Party or its Affiliates of the right to grant to another Party access, license, sublicense, or other right as provided herein, without violating the terms of any
agreement or other arrangement, existing before the Effective Date, with any Third Party. 

  

			
		  	2

 1.12. “Deliverables” includes Product Concepts, Accepted Product
Concepts, Draft Report, Final Report and any output of the Development Program insofar as it is provided for in Exhibit I and/or incorporates or relies on Relief Confidential Information and Relief IP 

1.13. “Development Program” has the meaning ascribed to it in Section 2.5.1. 

1.14. “Discloser” means the Party, or its Affiliates or Representatives, which discloses its own Confidential
Information. 
 1.15. “Draft Report” has the meaning ascribed to it in Section 2.2. 

1.16. “Effective Date” has the meaning ascribed to it in the Preamble. 

1.17. “EU5 Countries” means the United Kingdom, Germany, France, Spain and Italy. For clarity, the United Kingdom
remains EU5 Countries after so called Brexit for the purpose of this Agreement. 
 1.18. “Exclusion List” has the
meaning ascribed to it in Section 2.3. 
 1.19. “Final Report” has the meaning ascribed to it in
Section 2.2.3 
 1.20. “First Commercial Sale” means, with respect to a Accepted Product Concept, the first
commercial sale of such Accepted Product Concept by or on behalf of Relief to a Third Party (including wholesalers or distributors), after receipt of Regulatory Approval for such Accepted Product Concept. 

1.21. “Force Majeure Event” has the meaning ascribed to it in Section 9.5. 

1.22. “FTO” has the meaning ascribed to it in Section 2.2.4. 

1.23. “Identification Period” shall mean a period of twelve (12) months from the InveniAI’s receipt of the
Product Concept Identification Fees. 
 1.24. “IND” means Investigational New Drug. 

1.25. “Indication Focus” has the meaning ascribed to it in Section 2.1.2. 

1.26. “InveniAI Indemnitees” has the meaning ascribed to it in Section 9.2.2. 

1.27. “InveniAI IP” means all IP Rights owned or Controlled by InveniAI or its Affiliates either (i) prior to the
Effective Date, or (ii) independent of the Development Program or this Agreement (iii) Product Concepts other than Accepted Product Concepts developed under this Agreement. 

  

			
		  	3

 1.28. “IP Rights” means all vested, contingent and future
intellectual property rights including: (i) all inventions, materials, compounds, compositions, substances, methods, processes, techniques, know-how, technology, data, information, discoveries and
materials, including ideas, concepts, formulas, assays, practices, processes, software, devices, techniques, procedures, designs, compositions, constructs, compounds, plans, applications, research, preclinical and clinical data, regulatory
information, manufacturing process, scale-up and other technical data, reports, documentation and samples, including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and
analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, as well as study designs and protocols; assays and biological methodology and other results of any nature
whatsoever, and any Patents, trade secrets, confidential information, proprietary processes, or industrial rights directly or indirectly deriving therefrom; (ii) all trademarks, service marks, copyrights, designs, trade styles, logos, trade
dress, and corporate names, including all goodwill associated therewith; and (iii) any work of authorship, regardless of copyrightability, all compilations and all copyrights. 

1.29. “Joint Steering Committee” or “JSC” means the joint steering committee established by the
Parties as set forth in Section 2.4.1. 
 1.30. “Losses” has the meaning ascribed to it in Section 9.2.1.

 1.31. “Milestone Event” has the meaning ascribed to it in Section 5.2. 

1.32. “Milestone Fees” has the meaning ascribed to it in Section 5.2. 

1.33. “Milestone Payment” has the meaning ascribed to it in Section 5.2. 

1.34. “Mutual NDA” has the meaning ascribed to it in Recitals. 

1.35. “Net Sales” means the actual amounts received by Relief or its Affiliates from the sale by Relief, its
Affiliates or their licensees of the Accepted Product Concept(s) in the United States, EU5 Countries and Japan to Third Parties, less 

1.35.2. net of any of the following to the extent included in such amounts: (a) normal and customary trade and quantity discounts
actually given; and, in case of returns or rejections of the product(s), the associated credits and price adjustments; and (b) discounts, rebates, reimbursements, chargeback payments or commissions allowed or granted, and administrative fees
paid, to government agencies, managed health care organizations or trade customers, including wholesalers, health care administrators, patient assistance or similar programs, pharmacy benefit managers, health care institutions including hospitals
other distributors, pharmacies and other retailers, buying groups, health maintenance organizations, national, state/provincial, local, and other governments, their agencies and purchasers and reimbursers, any other providers of health insurance
coverage, and group purchasing organizations or other chain buying groups; and 
 1.35.2. (a) freight, postage, shipping, customs
duties and insurance charges; and (b) sales, value-added, and excise taxes, tariffs, and other taxes and government charges invoiced to Third Parties without markup; and (c) fees or other charges paid under the Patient Protection and
Affordable Care Act of 2010 or other similar legislation in foreign countries and d) any other items actually deducted from gross invoiced sales amounts as reported by Relief or its Affiliates in their financial statements in accordance with their
accounting standards, applied on a consistent basis. 

  

			
		  	4

 1.36. “Opt-in Fee” has the
meaning ascribed to it Section 5.2. 
 1.37. “Option Pool” has the meaning ascribed to it in
Section 2.2.3. 
 1.38. “Parties” means Relief and InveniAI and “Party” means either of Relief
or InveniAI. 
 1.39. “Patent(s)” means (a) any and all national, regional and international patents,
certificates of invention, applications for certificates of invention, priority patent filings and patent applications, including provisional patent applications, and (b) any renewal, divisional, continuation (in whole or in part), or request
for continued examination of any of such patents, certificates of invention and patent applications, and any and all patents (including utility models, petty patents and design patents) or certificates of invention issuing thereon, and any and all
reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing. 

1.40. “Person” means any individual, corporation, partnership, limited liability company, trust, governmental entity,
or other legal entity of any nature whatsoever. 
 1.41. “Platform” has the meaning ascribed to it in the Recitals.

 1.42. “Product Concept” has the meaning ascribed to it in the Recitals. 

1.43. “Product Concept Identification Fees” has the meaning ascribed to it in Section 5.1. 

1.44. “Purpose” has the meaning ascribed to it in Section 8.1. 

1.45. “Recipient” means the Party receiving Confidential Information from the other Party or its Affiliates or
Representatives. 
 1.46. “Regulatory Development Path” has the meaning ascribed to it in Section 2.1.3. 

1.47. “Regulatory Approval” means the approval of a governmental authority necessary to commercially distribute, sell,
market and use a Accepted Product Concept in a given country or regulatory jurisdiction in accordance with applicable laws and regulations. 

1.48. “Reformulation Opportunity” has the meaning ascribed to it in Section 2.1.1. 

1.49. “Re-Innovation and Reformulation Opportunity” has the meaning ascribed
to it in Section 2.1.1. 
 1.50. “Relief Indemnitees” has the meaning ascribed to it in Section 9.2.1.

 1.51. “Relief IP” means (a) all IP Rights owned or Controlled by Relief and its Affiliates (i) prior to
the Effective Date, (ii) independent of the Development Program or this Agreement, or (iii) generated without the use of any InveniAI IP or InveniAI Confidential Information and (b) all IP Rights for (i) the Accepted Product
Concepts and any content related to Accepted Product Concepts in the Final Report, and/or; (ii) any output of the Development Program insofar as it incorporates or relies on Relief Confidential Information and Relief IP. 

  

			
		  	5

 1.52. “Representatives” means employees, officers, agents,
subcontractors, consultants, Affiliates and/or any other Person acting on a Party’s behalf, individually or collectively, and which will be exposed to Confidential Information. 

1.53. “Senior Executive” has the meaning ascribed to it in Section 9.7. 

1.54. “Strategic Considerations” has the meaning ascribed to it in Section 2.1.4. 

1.55. “Successor” means any successor to a Party by way of (i) sale of all or substantially all of the assets of
a Party, (ii) stock sale or share exchange, or (iii) merger or similar reorganization transaction. 
 1.56.
“Term” has the meaning ascribed to it in Section 7.1. 
 1.57. “Third Party Claim” has the
meaning ascribed to it in Section 9.2.1. 
 1.58. “Third Party” means any Person other than Relief, InveniAI or
their respective Affiliates. 
 2. IDENTIFICATION AND DELIVERY OF PRODUCT CONCEPTS 

2.1. Identification Period. InveniAI, during the Identification Period, will utilize its Platform, and may rely on or
incorporate Relief IP and Relief Confidential Information, to: identify Product Concepts across rare diseases that may be suitable for Relief to (a) validate in animal model systems: and (b) conduct
IND-enabling studies on the Accepted Product Concepts. InveniAI shall use Commercially Reasonable Efforts to identify Product Concepts in accordance with the timeline described in Exhibit I hereof. Relief may
give reasonable cooperation and assistance in InveniAI’s identification activities. InveniAI will provide a monthly overview on its efforts and activities performed during the Identification Period. The Product Concepts will encompass the
following considerations: 
 2.1.1. Active Pharmaceutical Ingredients (APIs) of all approved drugs: 6000+ 

 

	 	•	 	 Re-Innovation and Reformulation Opportunity: Alignment of existing
API into a new indication with/without new formulation that offers benefit over existing drug by addressing significant unmet need 

  

	 	•	 	 Reformulation Opportunity: Same API, same indication with a novel formulation to offer benefit over
existing drug by addressing significant unmet need (for example [***]) 

 2.1.2. Indication Focus on
7000+ orphan diseases 
 2.1.3. Regulatory Development Path via 505(b)2 development 

  

			
		  	6

 2.1.4. Strategic Considerations: 

 

	 	•	 	 Concepts in alignment with Relief’s existing infrastructure: 

 

	 	•	 	 Formulation, development and commercial 

 

	 	•	 	 Defined regulatory path with end points defined with the FDA 

 

	 	•	 	 Availability of patient advocacy group 

 

	 	•	 	 Low investment for clinical trial and quicker path to market (3-5 years)

 2.2. Deliverables. InveniAI, by within twelve (12) months of the Effective Date will submit
for Relief’s review a draft report (the “Draft Report”) that: 
 2.2.1. Identifies InveniAI’s hypotheses;

 2.2.2. The landscape of up to six (6) Product Concepts identified and prioritized; 

2.2.3. Provides target product profiles (TPPs) including design of animal proof of validation study design for up to six
(6) Product Concepts (hereinafter the “Option Pool”). 
 2.2.4. includes a Freedom to Operate analysis
(“FTO”), that ascertains by execution of a proper patent and prior art search if the Product Concepts can be used by Relief for the purpose of their clinical development or commercialization worldwide. The FTO is only restricted to
patent searches and does not include legal recommendation 
 Relief may make comments on the Draft Report within sixty (60) days or other period if
agreed by the Parties from receipt of Draft Report and InveniAI will create and submit a revised report that makes commercially reasonable efforts to address Relief’s comments within thirty (30) days or other period if agreed by the
Parties from receipt of Relief’s comments. (the “Final Report”). 
 The Parties agree that, in case InveniAI’s activities under
Section 2.1 deviate from the timeline described in Exhibit I hereof, each Party shall have the right to request the Joint Steering Committee to discuss the reasons for delay and to discuss and agree in good faith about the required changes to
the timeline according to the provision of Section 2.4. 
 2.3. Exclusion from Collaboration. InveniAI provides in
the Exhibit II to this Agreement to Relief the list of rare diseases related to [***] (the “Exclusion List”) to avoid the conflict with InveniAI’s and its sister Affiliate, [***] internal projects. The Exclusion List shall be
out of the scope of this Collaboration Program. 
 2.4. Governance 

2.4.1. The Joint Steering Committee (JSC) shall have a total of six (6) members, with three (3) members appointed by
Relief and three (3) members appointed by InveniAI to (i) monitor the progress of the collaboration, (ii) ensure the coordination of project and regulatory activities by the respective Parties and timely completion of all work
(iii) discuss the selection of Product Concepts. JSC shall meet monthly or as otherwise agreed by the Parties, but no less than six (6) times per year which meetings shall not be more than eight weeks apart. Relief will have the final
decision authority on such issues that relate to this collaboration. 
 2.4.2. The JSC shall be formed within the term of four
(4) calendar weeks from the Effective Date. 

  

			
		  	7

 2.4.3. The JSC will be able to establish and delegate duties to sub-committees such as joint research committees to oversee and direct particular projects or activities at an appropriate time. 

2.5. Product Concept Evaluation. 

2.5.1. The Parties shall collaborate through the JSC and as otherwise agreed to by the Parties for InveniAI’s identification
activities for the Product Concepts during the Identification Period and during the period set forth in Section 2.6 (the “Development Program”). 

2.5.2. Upon delivery of Final Report, Relief will provide a written notice to exercise the right to acquire one or more Product
Concepts from the Final Report within a 180-day period. Notwithstanding the foregoing, in case Relief is required to acquire or license-in any IP Right from Third
Parties in order to be able to get ownership rights for one or more Product Concepts, the Parties shall discuss and agree in good faith about any longer period of time for Relief to provide the written notice required to get ownership rights for any
selected Product Concept. 
 2.5.3. Upon exercising the right and payment, Relief will get ownership rights for the Product Concepts
(“Accepted Product Concepts”). Save the longer period of time agreed pursuant to Section 2.5.2, if Relief does not acquire any Product Concept from the Option Pool within 180 days from delivery of the Final Report, InveniAI
will provide 2 additional Product Concepts (the “Additional Product Concepts”) for consideration within an additional term of 90 days. Save any longer period to be agreed between the Parties according to the provision of
Section 2.5.2, which shall also apply in relation to the Additional Product Concepts, Relief will have a 180-day period from receiving the Additional Product Concepts to decide whether to exercise its
right to acquire the Additional Product Concepts and provide written notice of same. Relief will have no right to acquire the Product Concepts provided in the initial Final Report, in case of requesting additional 2 Product Concepts. 

2.5.4. Relief will have the exclusive rights, inter alia, to continue IND-enabling
preclinical study and further development of the Accepted Product Concepts only. Accepted Product Concepts are subject to payments of success based milestones in Section 5.2. The Parties agree that Relief shall be responsible for and bear all
costs and expenses for intellectual property protection, development and commercialization of any Accepted Product Concepts. Nothing contained in this Agreement will be deemed to be a warranty by either Party that such Party can or will be able to
obtain Patents based on the activities conducted under the Development Program. 
 2.5.5. At all times, Relief and its Affiliates
shall have the right, but not the obligation, to totally or partially license the IP rights, commercial rights and any related rights on the Accepted Product Concepts to their licensees, subject to Relief’s payment obligations under Sections
5.2 and 5.3. Subject to 9.12.3, Relief and its Affiliate’s licensee shall benefit at all time of a perpetual license right under the InveniAI IP according to Section 4.1.6. 

2.6. Term of Development Program. Subject to Section 2.5.3, the Development Program shall expire upon either of the
earlier 1) the date Relief selects Accepted Product Concepts for further development and commercialization; or 2) One hundred and eighty days (180) days following the delivery of Final Report. 

  

			
		  	8

 3. EXCLUSIVITY 

3.1. Exclusivity. In addition to the restriction set out in Section 4.1 below, InveniAI shall not, itself or through
any of its Affiliates or any Third Party, research, develop, make, use, market, license, offer to sell, sell or otherwise commercialize any such Relief IP, including the Accepted Product Concepts and any subject matter related to Accepted Product
Concepts in the Final Report, and the Final Report’s core content regarding the Product Concepts (API-disease combinations). 

4. INTELLECTUAL PROPERTY 

4.1. Ownership of Product Concepts and IP Rights Developed under this Agreement. 

4.1.1. Subject to Section 4.1.2, as between the Parties, Relief shall be the sole and exclusive owner of all rights, title and
interest in and to the Accepted Product Concepts and any content related to Accepted Product Concepts in the Final Report. 
 4.1.2.
As between the Parties, InveniAI shall be the sole and exclusive owner of all rights, title and interest in and to any improvements or enhancements of the existing InveniAI’s AI methodologies and technology used by InveniAI to perform its
obligations hereunder. 
 4.1.3. Each Party shall take such actions, including executing and delivering IP Rights assignment
agreements, as are reasonably requested by the other Party to evidence or perfect the allocation of rights set forth in this Section 4.1. 

4.1.4. Each Party may pursue intellectual property protection for its IP Rights as it deems appropriate and at its own expense. 

4.1.5. Each Party may license, transfer, assign or otherwise dispose its own IP Rights freely without any restriction unless otherwise
specifically set forth in this Agreement. 
 4.1.6. Subject to Section 9.12, InveniAI grants Relief a non exclusive, upon paying
the Opt-in Fee, sub-licensable, free of charge, non transferable licence under the InveniAI IP to the extent necessary to allow Relief to exploit the Accepted Product
Concepts and any content related to Accepted Product Concepts in the Final Report worldwide. 
 4.2. Ownership of IP Rights
Developed Outside of this Agreement. 
 4.2.1. InveniAI has and shall retain all right, title and interest in and to, the
InveniAI IP, subject to the rights and licenses granted to Relief and its Affiliates as expressly set forth in this Agreement. 

  

			
		  	9

 4.2.2. Relief has and will retain all right, title and interest in and to, the Relief
IP, subject to the rights and licenses granted to InveniAI and its Affiliates as expressly set forth in this Agreement. 
 4.2.3.
Except for the rights and licenses expressly granted in this Agreement, InveniAI retains all rights under its intellectual property, including the InveniAI IP, and Relief retains all rights under its intellectual property, including the Relief IP,
and no rights shall be deemed granted by one Party to the other Party by implication, estoppel or otherwise. 
 4.3.
Development Program License Grants. Relief hereby grants to InveniAI and its Affiliates a worldwide, non-exclusive, non-transferable and royalty-free
license, without the right to sublicense, under Relief IP during the term of the Development Program only to the extent necessary or useful for InveniAI and its Affiliates to use the Relief IP to identify potential Product Concepts for Relief. For
clarity, a) InveniAI and its Affiliates are not granted any right or license to use the Relief IP to identify compounds or product opportunities for InveniAI or any of its Affiliates or a Third Party and b) upon expiry of the Development Program the
license shall be automatically terminated. 
 5. FEES AND PAYMENTS 

5.1. Product Concept Identification Fees. In consideration of InveniAI’s work to identify Product Concepts to Relief
during the Identification Period, Relief shall pay InveniAI, [***] due upon signing this Agreement. For the avoidance of doubt, InveniAI will have no obligation to commence work under this Agreement unless and until Relief pays the Product Concept
Identification Fees. 
 5.2. Milestone Fees. In consideration for the rights granted to Relief hereunder, Relief will
make the following payments (each a “Milestone Payment”) to InveniAI for each milestone associated with Accepted Product Concept (each a “Milestone Event”). 

 

					
	Success Based Milestones by Relief for clinical development and commercialization for Accepted Product Concepts:
	Milestones paid to InveniAI	 	  
 Transfer Fee upon Relief’s exercise of the option to acquire the
IP Rights related to Accepted Product Concepts (“Opt-in Fee”)
	 	  
 [***]

	 	  
 Upon issuance or allowance of a valid set of patent claims pertaining
to the Accepted Product Concept by the United States Patent & Trademark Office (USPTO)
	 	  
 [***]

	 	  
 Upon successful completion of a Phase 3 program
	 	  
 [***]

	 	  
 Regulatory Approval for the Accepted Product Concept in United
States
	 	  
 [***]

	 	  
 Regulatory Approval for the Accepted Product Concept in EU5
Countries
	 	  
 [***]

	 	  
 Regulatory Approval for the Accepted Product Concept in Japan
	 	  
 [***]

	 	  
 First Achievement of annual Net Sales related to the Accepted Product
Concept: $500M
	 	  
 [***]

	 	  
 First Achievement of annual Net Sales related to the Accepted Product
Concept: $1000M
	 	  
 [***]

  

			
		  	10

 5.3. Commercialization Payment. In further consideration for the
services performed for and the rights granted to Relief hereunder, beginning with the First Commercial Sale of each Accepted Product Concept, Relief shall pay to InveniAI in each of the United States, EU5 Countries and Japan and ending on the
earlier date of (a) termination of all valid claims of Patents covering a product preventing a Third Party from selling an AB Rated Product in the United States or comparable rating outside of United States, in each of the United States, EU5
Countries, Japan, or (b) the tenth (10th) anniversary of the First Commercial Sale in each of the United States, EU5 Countries and Japan, a royalty rate of [***] ([***])% on Net Sales of the Accepted Product Concept (“Commercialization
Payment”) payable to InveniAI sixty (60) days from each financial quarter closing. 
 5.4. Payment.
Relief will report all milestones stated in Sections 5.2 and 5.3 to InveniAI within thirty (30) Business Days of meeting the milestone event. InveniAI will provide an invoice for each payment to Relief appropriately, and Relief will make such
payment within sixty (60) days after receipt of the invoice. All payments and expense reimbursements shall be made by Relief in United States Dollars by wire transfer of immediately available funds to an account designated in writing by
InveniAI. Any payments made more than thirty (30) days after the date due shall bear interest at the rate permitted by law. 

5.5. Taxes. All payments of any amounts pursuant to this Agreement must comply with applicable tax withholding
obligations. After reasonable advance notice to the extent practical, Relief has the right to withhold and pay to applicable taxing authorities any amounts required to be withheld by any applicable laws from amounts payable to InveniAI. Relief will
promptly provide InveniAI with all relevant information and documentation with respect to the amounts withheld. For clarity, in no event will a) will the withholding payment be summed-up to the amount payable
to InveniAI and b) Relief be responsible for the payment of taxes levied on the income of any other Party pursuant to this Section 5.5. 

6. REPRESENTATIONS AND WARRANTIES 

6.1. Reciprocal Representations. Each Party hereby represents and warrants to the other Party that: 

6.1.1. it has the full power and authority to enter into this Agreement and to perform its obligations hereunder, and all required
corporate approvals have been obtained; 
 6.1.2. entering this Agreement will not constitute a breach of any agreement, contract,
understanding or obligation, including such Party’s documents of incorporation; and 

  

			
		  	11

 6.1.3. it is a corporation duly organized, validly existing under the laws of the
jurisdiction of its organization and it has all necessary corporate power and authority to carry on its business as currently conducted or proposed to be conducted; and 

6.2. InveniAI’s Representations. InveniAI represents and warrants to Relief that: 

6.2.1. Neither the Platform nor the Accepted Product Concepts, nor Relief’s use of the Accepted Product Concepts for its intended
purposes will infringe or misappropriate a Third Party’s IP Right; 
 6.2.2. it has sufficient knowledge, asset and personnel
required to perform all of its obligations under this Agreement and use and furnish those knowledge, asset and personnel in performing its obligation under this Agreement, such as but not limited to the regular interactions in the JSC as defined in
this Agreement; 
 6.2.3. it will use its best professional principles and practices in accordance with normally accepted industry
standards in performing its obligation under this Agreement; and 
 6.2.4. it has sufficiently secured information, computing, cyber
and communication technology system to prevent any security breach or any other network accidents from occurring which is normally required to the industry that InveniAI belongs to. 

6.3. Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THE REPRESENTATIONS AND WARRANTIES AND DISCLAIMERS DESCRIBED IN THIS ARTICLE 6 ARE EXCLUSIVE AND SUPERSEDE ANY OTHER WARRANTY LIMITATIONS AND DISCLAIMERS GIVEN BY EITHER PARTY WITH RESPECT TO THE
SUBJECT MATTER CONTAINED HEREIN, WHETHER WRITTEN OR ORAL. EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE OR USE, NON-INFRINGEMENT, VALIDITY AND
ENFORCEABILITY OF PATENTS, OR THE PROSPECTS OR LIKELIHOOD OF DEVELOPMENT OR COMMERCIAL SUCCESS OF ANY ACCEPTED PRODUCT CONCEPT. 
 7.
TERM AND TERMINATION 
 7.1. Term. The term of this Agreement (the “Term”) will commence on
the Effective Date and continue in effect until InveniAI’s receipt of the last payment required by Relief under the Milestone Payments and the Commercialization Payments, unless earlier terminated in accordance with this Article 7 or extended
by the Parties by written agreement. 
 7.2. Termination for Cause. Each Party may terminate this Agreement before the
end of the Term upon written notice to the other Party if the other Party is in material breach of this Agreement, and such breaching Party has not cured such breach within ninety (90) days after notice is received by such non-breaching Party regarding such breach. Any such termination will become effective at the end of such ninety (90)-day period unless the breaching Party has cured any such
breach prior to the end of such period. 

  

			
		  	12

 7.3. Termination for Bankruptcy. Either Party may terminate this
Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state or country a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of the other Party or of substantially all of its assets; or if the other Party proposes a written agreement of composition or extension of substantially all of its debts; or if the other Party will be served with an involuntary
petition against it, filed in any insolvency proceeding, and such petition will not be dismissed within ninety (90) days after the filing thereof; or if the other Party will propose or be a party to any dissolution or liquidation; or if the
other Party will make an assignment of substantially all of its assets for the benefit of creditors. 
 7.4. Effect of
Termination. 
 7.4.1. The expiration or termination of this Agreement for any reason shall not (a) release InveniAI or
Relief from any liability which, at the time of such expiration or termination, has already accrued to such Party or which is attributable to a period prior to the effective date of such expiration or termination, (b) excuse Relief from its
payment obligations under Sections 5.2 and 5.3 without regard to whether the obligation accrues during or after the Term unless in case of Relief’s termination in accordance with Section 7.2, whereas Relief shall not be responsible to
perform its payment obligations after that InveniAI’s breach takes place, or (c) preclude InveniAI or Relief from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this
Agreement. 
 7.4.2. All rights and licenses granted under or pursuant to this Agreement are, and will otherwise be deemed to be, for
purposes of Bankruptcy Laws, licenses of rights to “intellectual property” as defined under the Bankruptcy Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is
rejected as provided in such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its Successors and assigns (including, a trustee) will
perform all of the obligations provided in this Agreement to be performed by such Party. If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as provided in the Bankruptcy Laws and the
other Party elects to retain its rights hereunder as provided in the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including
debtor-in-possession) and its Successors and assigns (including, a Title 11 trustee), will provide to such other Party copies of all information necessary for such other
Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party’s written request therefor. All rights, powers and remedies of the non-bankrupt Parties
as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including, the Bankruptcy Laws) in the event of the commencement of a case by or against a
Party under the Bankruptcy Laws. It is the intention and understanding of the Parties to this Agreement that the rights granted to the Parties under this Section 7.4.2 are essential to the Parties’ respective businesses and the Parties
acknowledge that damages are not an adequate remedy. 

  

			
		  	13

 8. CONFIDENTIALITY 

8.1. Non-Disclosure Obligation. Other than as expressly authorized by this
Agreement or otherwise agreed to in writing by the Parties, the Parties agree that the Recipient undertakes to treat and maintain, and ensure that its Representatives will treat and maintain, in strict confidence and secrecy, Confidential
Information that is disclosed to it by the Discloser, will keep in confidence the existence and contents of this Agreement, and will not disclose, publish, or disseminate in any manner, any of Discloser’s Confidential Information to a Third
Party other than to those of its Representatives with a need to know the same for the purpose of performing its activities and obligations under this Agreement (the “Purpose”). Recipient will, in performing its duties and
obligations hereunder, use at least the same degree of care as it does with respect to its own confidential information of like importance but, in any event, at least reasonable care. Recipient agrees to be responsible for any use or disclosure of
Discloser’s Confidential Information to any of its said Representatives. For the avoidance of doubt, any concept, data, idea, right and other all information set forth in Section 4.1.1 shall be deemed as Relief’s Confidential
Information (Relief is the Discloser) and those in Section 4.1.2 shall be deemed as InveniAI’s Confidential Information (InveniAI is the Discloser). 

8.2. Exclusions. The undertakings and obligations under Sections 8.1, 8.3 and 8.5 will not apply to any part of the
Confidential Information which a Party can prove: 
 8.2.1. was known to the Recipient prior to disclosure by the Discloser as
evidenced by written records; 
 8.2.2. was generally available to the public prior to disclosure to the Recipient; 

8.2.3. is disclosed to Recipient by a Third Party who is not bound by any confidentiality obligation, having a legal right to make such
disclosure; 
 8.2.4. has become, through no act or failure to act on the part of the Recipient, public information or generally
available to the public; 
 8.2.5. is independently developed by the Recipient as evidenced by written records without reference to
or reliance upon the Discloser’s Confidential Information; or 
 8.3. The Recipient may disclose the Discloser’s
Confidential Information as required (and only to the extent of such requirement) to by law, court order, or governmental regulation (including securities laws and/or exchange regulations), provided that the Recipient to the extent permitted by law
gives the Discloser reasonable notice prior to any such disclosure and reasonably cooperates (at the Discloser’s expense) with the Discloser in obtaining a protective order or other suitable protection from disclosure (if available) with
respect to such Confidential Information. Notwithstanding the foregoing and for the sake of clarity, a Party shall have at all times the right to submit a copy of the present Agreement for disclosure purposes in accordance with securities laws
and/or exchange regulations, without receiving any prior written consent from the other Party. 

  

			
		  	14

 8.4. Irreparable Harm. The Parties acknowledge that each Party’s
respective Confidential Information is of special and unique significance to each of them and that any unauthorized disclosure or use of the Discloser’s Confidential Information could cause irreparable harm and significant injury to the
Discloser, which may be difficult to ascertain. Accordingly, any breach of this Agreement may entitle the aggrieved Party, in addition to any other right or remedy that it may have available to it by law or in equity, to remedies of injunction,
performance and other relief, including recourse in a court of law. 
 8.5. Notice. Each Party agrees to inform the
other Party of any breach or threatened breach of the provisions hereof by its Representatives. 
 8.6. Survival. The
provisions relating to confidentiality in this Article 8 will remain in effect during the Term and for a period of five (5) years after the expiration or termination of the Term. 

8.7. Return or Destruction of the Confidential Information. Upon termination of this Agreement for any reason, or upon
Discloser’s request at any time, Recipient will promptly return to Discloser or destroy, at the direction of Discloser, all originals and copies of any Confidential Information and destroy all information, records and materials developed
therefrom, provided, however, one copy may be retained in Recipient’s legal files for archival purposes as a means of determining any continuing obligation hereunder and the Recipient shall not be required to delete the Confidential Information
from back-up archival storage. Such destruction shall be certified in writing to Discloser. 
 9.
MISCELLANEOUS 
 9.1. Publicity. InveniAI, upon receipt of prior written approval of Relief, may issue
reasonable press releases, disclose the existence this Agreement and InveniAI’s relationship with Relief, and disclose to investors and potential investors, under confidentiality obligations consistent with Article 8, that it is providing or
has provided services using the Platform to Relief, provided that, in all cases, InveniAI does not disclose any Relief Confidential Information. Relief may issues press release in relation to the existence of this Agreement and Relief’s
relationship with InveniAI without receiving any prior written consent from InveniAI provided that, in all cases, Relief does not disclose any InveniAI Confidential Information. 

9.2. Indemnification. 

9.2.1. Indemnification of Relief. InveniAI shall defend, indemnify and hold harmless each of Relief and its Affiliates,
and the directors, officers, stockholders and employees of such entities and the Successors and assigns of any of the foregoing (the “Relief Indemnitees”) from and against any and all losses, liabilities, damages, penalties, fines,
costs and expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Losses”) from any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claim”) incurred by
any Relief Indemnitee, arising from, or occurring as a result of (a) the willful misconduct or gross negligence of InveniAI or its Affiliates, (b) any breach of any representation or warranty made by InveniAI under this Agreement, or
(c) misappropriation of all or part of a Product Concept from a Third Party by InveniAI or its Affiliates; except in each case to the extent such Third Party Claims fall within the scope of the indemnification obligations of Relief set forth in
Section 9.2.2. 

  

			
		  	15

 9.2.2. Indemnification of InveniAI. Relief shall defend, indemnify and
hold harmless InveniAI, its Affiliates, and the directors, officers, stockholders and employees of such entities and the Successors and assigns of any of the foregoing (the “InveniAI Indemnitees”) from and against any and all Losses
from any Third Party Claim incurred by any InveniAI indemnitee, arising from or occurring as a result of (a) the willful misconduct or gross negligence of Relief or its Affiliates, (b) any breach of any representation or warranty made by
Relief under this Agreement, or (c) the use of any Product Concepts by Relief, including development or commercialization; except in each case to the extent such Third Party Claims fall within the scope of the indemnification obligations of
InveniAI set forth in Section 9.2.1. 
 9.2.3. Procedure. A Party that intends to claim indemnification under this
Section 9.2 shall promptly inform the indemnifying Party in writing of any Third Party Claim, in respect of which the indemnitee intends to claim such indemnification. The indemnified Party shall provide the indemnifying Party with reasonable
assistance, at the indemnifying Party’s expense, in connection with the defense of the Third Party Claim for which indemnity is being sought. The indemnitee may participate in and monitor such defense with counsel of its own choosing at its
sole expense; provided, however, the indemnitor shall have the right to assume and conduct the defense of the Third Party Claim with counsel of its choice. The indemnitor shall not settle any Third Party Claim without the prior written consent of
the indemnified Party, not to be unreasonably withheld or delayed, unless the settlement involves only the payment of money. So long as the indemnitor is actively defending the Third Party Claim in good faith, the indemnitee shall not settle any
such Third Party Claim without the prior written consent of the indemnifying Party. If the indemnitor does not assume and conduct the defense of the Third Party Claim as provided above, (a) the indemnitee may defend against, and consent to the
entry of any judgment or enter into any settlement with respect to the Third Party Claim in any manner the indemnitee may deem reasonably appropriate (and the indemnitee need not consult with, or obtain any consent from, the indemnitor in connection
therewith), and (b) the indemnitor will remain responsible to indemnify the indemnitee as provided in this Section 9.2. The failure to deliver written notice to the indemnitor within a reasonable time after the commencement of any action
with respect to a Third Party Claim shall only relieve the indemnitor of its indemnification obligations under this Section 9.2 if and to the extent the indemnitor is actually prejudiced thereby. 

9.3. Insurance. Each Party, at its own expense, shall maintain a program of insurance in amounts and types consistent
with industry standards for a company in a similar position to such Party during the Term. 
 9.4. Independent
Contractors. Each Party shall be and shall act as an independent contractor and not as an agent or partner of, or joint ventures with the other Party for any purpose and neither Party shall have the right, power, or authority to act or
create any obligation, express or implied, on behalf of the other Party. 
 9.5. Force Majeure. If the performance of
any part of this Agreement by either Party (other than making payments when due) is prevented, restricted, interfered with or delayed by any reason or cause beyond the reasonable control of such Party and which had been unforeseeable by such Party
(including fire, flood, earthquake, storm, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or other labor disturbance, shortage of raw materials, regulatory hold, epidemic, pandemic, failure or default
of public utilities or common carriers, acts of God or any acts, omissions or delays in acting of the other Party) (a “Force Majeure Event”), the Party so affected will, upon giving written notice to the other Party, be excused from
such performance to the extent of such Force Majeure Event, provided that the affected Party will use its substantial efforts to avoid or remove such causes of non-performance and will continue performance
with the utmost dispatch whenever such causes are removed. Should the Force Majeure Event continue for a period of three (3) months, Relief shall have the right to terminate this Agreement on fifteen (15) days written notice. 

  

			
		  	16

 9.6. Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF
CONFIDENTIALITY PROVISIONS, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, NO PARTY OR ANY OF ITS AFFILIATES WILL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, INDIRECT, AGGRAVATED, EXEMPLARY OR PUNITIVE DAMAGES
(INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) IN CONNECTION WITH THIS AGREEMENT, REGARDLESS OF WHETHER SUCH DAMAGES ARE FORESEEABLE, AND WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR
OTHERWISE, ARISING OUT OF THIS AGREEMENT. FOR THE SAKE OF CLARITY, NOTHING IN THIS AGREEMENT SHALL EXCLUDE OR LIMIT THE LIABILITY OF EITHER PARTY TO THE EXTENT THAT SUCH EXCLUSION OR LIMITATION IS NOT PERMITTED UNDER THE GOVERNING LAW DETERMINED AT
SECTION 9.9. 
 9.7. Dispute Resolution. The Parties recognize that disputes as to certain matters may from time to
time arise during the Term that relate to interpretation of a Party’s rights and/or obligations hereunder or any alleged breach of this Agreement. If the Parties cannot resolve any such dispute within thirty (30) days after written notice
of a dispute from one Party to another, either Party may, by written notice to the other Party, have such dispute referred to the President & CEO of InveniAI and the President and Representative Director or other senior management
designated by him/her of Relief (collectively, the “Senior Executives”). The Senior Executives shall negotiate in good faith to resolve the dispute within thirty (30) days. During such period of negotiations, any applicable
time periods under this Agreement shall be tolled. Such resolution, if any, by the Senior Executives shall be final and binding on the Parties. If the Senior Executives are unable to resolve the dispute within such time period, either Party may
submit such dispute for arbitration pursuant to Section 9.9, subject to the terms and conditions of this Agreement and the other agreements expressly contemplated hereunder. Notwithstanding anything in this Section 9.7 to the contrary,
InveniAI and Relief shall each have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of that Party, subject to Section 9.9. 

9.8. Notices. All notices, requests, demands, claims, and other communications permitted or required to be given under
this Agreement must be in writing and will be deemed duly given and received: (a) if personally delivered, when so delivered; (b) if sent through an express commercial delivery, upon receipt; or (c) if sent by email, on receipt of
acknowledgment from the intended recipient. 
  

			
	 To InveniAI:
	  	To Relief:
	 InveniAI LLC
	  	Relief Therapeutics Holding AG
	 2614 Boston Post Road
	  	Bâtiment F2/F3, Avenue de Sécheron 15,
	 Suite 33B, Guilford, CT 06437
	  	1202 Genève, Switzerland
	 Attention: Krishnan Nandabalan
	  	Attention: Jeremy Meinen
	 Email: knandabalan@inveniai.com
	  	Email: jeremy.meinen@relieftherapeutics.com

  

			
		  	17

 9.9. Governing Law; Arbitration. This Agreement shall be interpreted
and construed under the laws of the State of New York without regard to its conflicts of laws principles. If any dispute which cannot be resolved by the Senior Executives is referred for arbitration pursuant to Section 9.7, then such dispute
shall be finally settled by arbitration in accordance with the Rules of the American Arbitration Association then in effect. The place of Arbitration shall be the State of New York, USA and the language to be used in the arbitral proceedings shall
be English. Any award made hereunder may be entered into any court or tribunal having jurisdiction hereof. 
 9.10. Entire
Agreement. This Agreement constitutes the entire agreement among the Parties hereto with respect to the subject matter hereof and supersedes all prior understandings whether written or oral. This Agreement may be modified, amended or waived,
in whole or in part, only by written agreement of both Parties. 
 9.11. Severability. If any term or condition of this
Agreement is found to be invalid or unenforceable by any competent court, such term or condition shall be ineffective only to the extent that it is in contravention of applicable law, without invalidating the remaining terms and conditions. 

9.12. Assignment. 

9.12.1. InveniAI may assign this Agreement without the prior written consent of Relief: a) at any time to an Affiliate; b) starting
from the time of completion of the Development Program to a Third Party. 
 9.12.2. Relief may totally or partially assign this
Agreement to an Affiliate or any Third Party without prior written consent of InveniAI. 
 9.12.3. This Agreement shall be binding
upon and inure to the benefit of the Parties and their Successors and permitted assigns, provided that the assigning Party shall be obliged to cause its Successors or assignees to submit to the assigned Party a written undertaking that such
Successors or assigns shall perform and comply with any and all obligations under this Agreement. 
 9.13.
Construction. The section headings in this Agreement are for convenience of reference only and will in no way define, limit, extend, or describe the scope of intent of any provisions of this Agreement. Unless otherwise specifically
provided in this Agreement, the term “or” will not be deemed to be exclusive, and the terms “including,” “such as,” and words of similar import will not be deemed to limit the language preceding such term, but rather
will be deemed to mean “including without limitation.” This Agreement will be considered for all purposes as having been prepared through the joint efforts of the Parties; no presumption will apply in favor of either Party in the
interpretation of this Agreement or in the resolution of any ambiguity of any provision in this Agreement based on the preparation, substitution, submission, or other event of negotiation, drafting, or execution of this Agreement. 

  

			
		  	18

 9.14. Waiver of Breach. No delay or waiver by either Party of any
condition or term in any one or more instances will be construed as a further or continuing waiver of such condition or term or of another condition or term. 

9.15. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to perform all
such other acts, as may be necessary or appropriate in order to carry out the Purposes and intent of this Agreement. 
 9.16.
Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party will agree to cause its Affiliates to perform such obligations. Any Party may contract with one or more of its
Affiliates to perform its obligations hereunder, provided that such Party will remain liable hereunder for the prompt payment and performance of all its respective obligations hereunder and any acts/omissions of such Affiliates as it relates to the
services. 
 9.17. Modification. No amendment or modification of any provision of this Agreement will be effective
unless in a prior writing signed by all Parties hereto. No provision of this Agreement will be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and
signed by all Parties hereto. All purchase orders, acknowledgments and other business forms issued by either Party are for the convenience of the issuing Party, and will not modify or supplement this Agreement even if countersigned or otherwise
accepted by the other Party. 
 9.18. No Third Party Beneficiaries. No Person other than the Parties and their
respective permitted Successors and assigns hereunder will be deemed an intended beneficiary hereunder, nor have any right to enforce any obligation of any Party to this Agreement. 

9.19. Survival. Expiration or termination of this Agreement will not relieve the Parties of any rights or obligation
accruing prior to such expiration or termination. In addition, upon expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement will terminate, except those described in the following Sections and
Articles: Articles 1, 3, 4, 5, 6, 8 and 9 (excluding Section 9.1); Section 7.4. 
 9.20. Counterparts. This
Agreement may be executed in any number of counterparts each of which will be deemed an original, and all of which together will constitute one and the same instrument. This Agreement may be executed by .pdf or other electronically transmitted
signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures. 
 Remainder of page
intentionally left blank. Signature page follows. 

  

			
		  	19

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective
Date. 
  

									
	INVENIAI LLC	 	 	 	RELIEF THERAPEUTICS HOLDING SA
					
	By:	 	/s/ Aman Kant	 		 	By:	 	/s/ Jeremy Meinen
	Name:	 	Aman Kant	 		 	Name:	 	Jeremy Meinen
	Title:	 	Chief Business Officer	 		 	Title:	 	VP Finance and Administration
	 	 	11/23/2021	 	 	 	 	 	11/23/2021

  

			
		  	20EX-10.7(A)

 Exhibit 10.7(A) 

CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 Master Service Agreement 

on 
 Order to CashService 

between 
 APR Applied Pharma Research s.a. 

Via Corti 5 
 6828 Balerna 

Switzerland 
 - in the following referred to as “APR”
— 
 and 
 Arvato Services Italia S.r.l. 

Via Zanica, 19/K 
 24050 Grassobbio (BG) 

Italy 
 - in the following referred to as
“Arvato’ and/or the ‘Service Provider”- 
 - each of the above a “Party”, and collectively the
“Parties”, 

 Table of Contents 
  

							
	1.	  	Interpretations and Definitions	  	 	5	 
			
	2.	  	Purpose & Scope of the Agreement	  	 	7	 
			
	3.	  	Arvato’s Services and Obligations	  	 	8	 
			
	4.	  	Pricing and Terms of Payment	  	 	9	 
			
	5.	  	APR’s Obligations	  	 	10	 
			
	6.	  	Sub-Contractors	  	 	11	 
			
	7.	  	Storage Area	  	 	11	 
			
	8.	  	Property	  	 	11	 
			
	9.	  	Freight Management/Shipment of Products	  	 	11	 
			
	10.	  	Inventory/Stock Taking	  	 	13	 
			
	11.	  	Liability/Indemnification	  	 	13	 
			
	12.	  	Insurance	  	 	15	 
			
	13.	  	Force Majeure	  	 	15	 
			
	14.	  	Confidentiality	  	 	15	 
			
	15.	  	Data Protection	  	 	16	 
			
	16.	  	Information and Regulatory Assistance	  	 	16	 
			
	17.	  	Exclusion of Transfer of Personnel	  	 	17	 
			
	18.	  	Intellectual Property Rights, Rights of Use	  	 	17	 
			
	19.	  	Term and Termination	  	 	18	 
			
	20.	  	Public Relations and References	  	 	19	 
			
	21.	  	Export Control	  	 	20	 
			
	22.	  	Bertelsmann Code of Conduct	  	 	20	 
			
	23.	  	Dispute Resolution	  	 	20	 
			
	24.	  	Miscellaneous	  	 	21	 
			
	Schedule A:	  	RFP Document	  	 	24	 
			
	Schedule B:	  	BRD	  	 	25	 

							
			
	Schedule C:	  	FRD	  	 	26	 
			
	Schedule D:	  	Pricing and Assumptions	  	 	27	 
			
	Schedule E:	  	Original Volumes	  	 	29	 
			
	Schedule F:	  	Arvato Subcontractors	  	 	30	 
			
	Exhibit 1:	  	Quality Agreement	  	 	31	 
			
	Exhibit 2:	  	GDPR – Appointment of Arvato as external data processor	  	 	32	 

 THIS MASTER SERVICE AGREEMENT ON ORDER TO CASH SERVICES 

IS MADE AND ENTERED INTO BY AND BETWEEN 
  

	(1)	 APR Applied Pharma Research s.a., a Swiss corporation registered with the commercial register of Ticino
under registration number CHE-101.714.120 and with its registered office at Balerna, Switzerland, via Corti 5 (“APR”), 

 

	(2)	 ARVATO SERVICES ITALIA S.R.L., an Italian limited liability company registered with the commercial
register at the local court of Bergamo under registration number BG-353384 and with its registered office at Via Zanica, 19/K, Grassobbio (BG), Italy (“Arvato” and/or the “Service
Provider”), 

 WHEREAS, APR is contracting comprehensive logistics and order to cash services for its Products under
the terms and conditions set forth in this Agreement. 
 WHEREAS, Arvato is a provider of such logistics and order to cash services. 

WHEREAS, Arvato has agreed to provide to APR the Services specified in Schedule B (Business Requirements Document) related to the distribution
of APR’s Products in the Territory on the terms and conditions set forth herein. 
 WHEREAS, The Parties enter this Agreement effective as of
September 1st 2018 (hereinafter referred to as “Effective Date”) and into a Quality Agreement which is attached to this Agreement as Exhibit 1 which is (together with all attachments in their respective form) an integral part
of this Agreement. 
 NOW, THEREFORE, for and in consideration of the agreements set forth below APR and Arvato agree as follows: 

	1.	 Interpretations and Definitions 

 

	(1)	 Headings, sub-headings and content pages of this Agreement or any
Schedule or any Exhibit are for ease of reference only, and shall not affect the interpretation of this Agreement, the Schedules and/or Exhibits. “Section” refers to sections of text which are marked with Arabic numerals
[e.g. 1], and “Clause” refers to sections of text within a specific Section which are marked with Arabic numerals in parentheses [e.g. (1)]. 

  

	(2)	 The word “include(s)” or “including” shall be construed without limiting the
generality of any preceding words or concepts. References to the singular include the plural and vice versa. “Writing” will include any modes of reproducing words in a legible and
non-transitory form, and for the avoidance of doubt, this shall not include electronic mail (“Email”), unless otherwise expressly and unambiguously stated in the Agreement.

  

	(3)	 A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time. A reference to a statute or statutory provision shall include all subordinate legislation made from time to time under that statute or statutory provision. 

 

	(4)	 Capitalized terms used in this Agreement shall have the following meaning, unless the context otherwise
requires: 

 Affiliates shall mean any entity, which is from time to time directly or indirectly controlled by a
Party “Control” means, with regard to an entity the legal, beneficial or equitable ownership, directly or indirectly, of more than fifty percent (>50%) or more of the capital stock (or other ownership interest, if not a corporation) of
such entity ordinarily having voting rights, or the equivalent right under contract to control management decisions with regard to relevant subjects). 

Applicable Law shall mean all applicable international, national, regional and local laws, rules, regulations and guidance which are in
force from time to time including without limitation Regulatory Authority rules and regulations, decisions and industry codes (including any modification or re-enactment thereto) applicable to distributors of
medicinal and/or FSMP products for human use and the activities or interactions under this Agreement, including GDP distributors. 

Breaching Party shall have the meaning as set forth in Section 19.(4) of this Agreement. 

Bonus / Malus shall have the meaning as set forth in Section 9.(4) of this Agreement. 

Business Day(s) shall mean a day on which the clearing banks in Bergamo (Italy)are open for normal banking business and offering a full
range of services, excluding Saturdays, Sundays and bank holidays in Italy. 
 Carrier shall mean a company specified in Schedule
B that carries goods from one place to another, including but not limited to freight forwarder, forwarder, or forwarding agent. 

Confidential Information shall mean all non-public information relating to a Party or any of its
Affiliates which is in oral, written, electronic or any other form disclosed by a Party (herein referred to as “Disclosing Party”) to the other Party (herein referred to as “Recipient”). Confidential Information
shall include prices, technological or organizational systems, customers, personnel, business activities, databases, Intellectual Property, the terms and conditions of this Agreement and other information in relation to it, which is either
specifically marked as confidential, or which is reasonably or customarily considered to be of a confidential, proprietary or otherwise sensitive nature. Confidential Information shall not include any information, which (i) was in
Recipient’s lawful possession without a confidentiality obligation prior to the disclosure, or (ii) is or becomes publicly available without breach by the Recipient, or (iii) is rightfully obtained by the Recipient from a Third Party,
who has the right to transfer or disclose it on a non-confidential basis, or (iv) as evidenced by the records of the Recipient is independently developed by the Recipient without any reference to
Confidential Information of the Disclosing Party. 

 Customer shall mean a pharmacy, hospital or wholesaler which orders, from APR or any
of its Affiliates, APR’s Products. 
 Effective Date has the meaning given in the preamble of this Agreement. 

Facility Logistics Center shall mean Arvato’s facility located at Calcinate (BG) Italy, or any other Arvato warehousing and
distribution facility approved by APR in writing prior to its use by Arvato in connection with the Services. 
 GDP shall mean the
applicable guidelines on good distribution practice of medicinal products for human use of the European Union including but not limited to to the principles stated in Directive 2001/83/EC and as outlined in the guidelines on GDP of medicinal
products for human use (94/C 63/03), guidelines on good distribution practice of medicinal products (2013/C 343/01) as amended and applicable from time to time. 

FSMP shall mean food specially processed or formulated and intended for the dietary management of patients, including infants, with a
limited, impaired or disturbed capacity to take, digest, absorb, metabolize or excrete ordinary food and be used/assumed under medical supervision. 

GMP shall mean the applicable guidelines on good manufacturing practice of FSMP products for human use of the European Union Union as
amended and applicable from time to time. 
 HACCP shall mean the Hazard Analysis and Critical Control Point for food safety
management system for Nutritional Supplements and FSMP. 
 Initiating Party shall have the meaning as set forth in Section 19.(4)
of this Agreement. 
 Intellectual Property shall mean any names, trademarks, service marks, patents trade names and/or logos, domain
names, documentation, know-how or other material protected by copyrights or other intellectual property rights, including software solutions. APR Intellectual Property shall mean any Intellectual
Property controlled by APR or its Affiliates at the Effective Date or at any time during the term of this Agreement and which is used in connection with the Services to be performed under this Agreement or otherwise in connection with this
Agreement. Arvato Intellectual Property shall mean any Intellectual Property controlled by Arvato or its Affiliates at the Effective Date or at any time during the term of this Agreement. Within the meaning of this definition, the term
control shall mean the possession of the ability to grant the right to, or of a licence or sublicense, without violating the terms of any agreement or other arrangement with any Third Party existing at the time of the grant, licence or sublicense.

 Notification to ship shall mean APR’s written instruction to Arvato and/or prior written authorisation given by APR to ship
Product(s) to APR’s customers. 

 Occurrence shall mean an individual Order. 

Order shall mean either a notification to ship or orders for Products placed by APR’s Customers directly at Arvato through the
Logistics Centre. 
 Original Volumes shall have the meaning as set forth in Section 19.(2) of this Agreement. 

Product(s) shall mean the ready-to-sell, finished
packaged and labelled final product form of any of the FSMP product(s) listed in Schedule B, as amended or modified from time to time upon mutual written agreement of the Parties. 

Regulatory Authority shall mean any international. European, national, regional or local agency, authority, department, inspectorate,
minister, ministry official, parliament, public or statutory person (whether autonomous or not) of any government of any country in the Territory, having jurisdiction over any of the activities contemplated by this Agreement or the Parties. 

Services shall mean all services to be provided by Arvato to APR under this Agreement as set forth in Schedule B, in connection
with the Quality Agreement, as set forth in Exhibit 1 as amended or modified from time to time upon mutual written agreement. 

Service Center Logistic Centre shall mean an information and service centre for APR’s Customers which shall, among other things and
without limitation, be the central point for the taking and processing of Orders, the tracking of Order Recalls and Returns, the invoicing for Products to be shipped in accordance with this Agreement and generally the handling of all queries
concerning Orders, invoicing, tracking. returns, recalls complaints or any other issues relating to lost or damaged Product(s). It will be provided without additional remuneration for APR by Arvato, unless specifically agreed in this Agreement. 

Subcontractor shall mean a Third Party, which Arvato selects, qualifies and engages to provide Services under this Agreement and listed
under Schedule F to this Agreement. 
 Term shall have the meaning defined in Section 19 Clause 15(1) of this Agreement.

 Territory shall mean the countries of Italy, Germany and Switzerland as better specified under Schedule B, as amended or
modified from time to time upon mutual written agreement of the Parties. 
 Third Party shall mean any person or entity other than the
Parties or their Affiliates. 
  

	2.	 Purpose & Scope of the Agreement 

 

	(1)	 This Agreement sets forth the terms and conditions under which Arvato will provide the Services for APR within
the Territory. In carrying out their duties and obligations under this Agreement the Parties will act in accordance with good faith, fair dealing and best intention in order to establish a long-term and reliable partnership. 

 

	(2)	 The Service Provider shall accept for storage at the Facility on behalf of APR the quantity of Product that
Arvato has collected at the third party’s facility indicated by APR in accordance with the procedure described in Schedule B (the “BRD”). APR will submit a forecast of such quantities to the Service Provider on a
quarterly basis. The Service Provider shall ensure that it has sufficient capacity to perform the Services, including when the demand for products exceeds APR’s forecast by more than 30%. The Service Provider shall not be obliged to meet the
agreed Service Level to the extent that the actual volume differ from the forecast by more than 15%, The difference between the forecast and the actual volumes will be calculated on monthly basis. 

	(3)	 APR hereby appoints Arvato to act as APR’s exclusive provider for the Services with respect to the
Product(s) within the Territory. During the term of the Agreement, APR may not enter into any agreements with Third Parties — including but not limited by awarding contracts to or through its Affiliates — regarding Services with respect to
the Product(s) within the Territory. 

  

	(4)	 Arvato has agreed to set up the Logistic Centre as the first point for receiving Orders. Unless expressly
provided to the contrary herein or in the Schedules to this Agreement, Arvato will receive such Orders directly from APR’s Customers. Arvato shall not act as APR’s salesman, agent or legal representative. It is understood that APR is
solely responsible for marketing and selling the Product(s) to its Customers and that all rights and duties arising out of, or in connection with, contracts between APR and its Customers do not bind or affect Arvato. As far as Arvato is contacting
Customers of APR under this Agreement Arvato is acting as APR’s messenger only. 

  

	(5)	 Neither Arvato nor its Affiliates shall act as a distributors or commercial agents of the Products inside the
Territory. In particular, Arvato and its Affiliates (i) shall not purchase, distribute or sell any Product to any purchaser in the Territory in its own name and for its own account and (ii) shall not negotiate the sale of Products on
behalf of APR or negotiate and conclude such transactions on behalf of or in the name of APR and (iii) shall not otherwise solicit or promote the Product in the Territory. 

 

	3.	 Arvato’s Services and Obligations 

 

	(1)	 Arvato performs the Services as described in Schedule B (BRD) as specified in the standard operating
procedures (“SOPs”) and the key performance indicators (the “KPI’s”) pursuant to Schedule B, each on the terms and conditions set out in this Agreement and the Quality Agreement including all its
attachments to be entered into by the Parties to be attached hereto as Exhibit 1. 

  

	(2)	 Arvato shall act in accordance with Applicable Law, GDP and HACCP at a standard to be expected from a
reputable, specialized and professional logistics provider in the pharmaceutical sector. 

  

	(3)	 The SOPs and/or the Quality Agreement will be adapted in good faith to any mandatory legal requirement or any
requirement imposed by the Regulatory Authorities, or if APR reasonably requests such change, provided that only the costs and expenses related to the adaptation to requirements imposed by Applicable Law, GDP, HACCP and Regulatory Authorities that
are in the sphere of the activities of Arvato, shall be totally sustained by Arvato (the “Compulsary Changes”). APR will, as soon as practicable, inform Arvato about any such change request in writing and Arvato will, subject to the
following, comply with any such change request without undue delay. Except in the event of Compulsary Changes, in the event the requested change leads to an increase in Arvato’s costs, the Parties shall negotiate an appropriate price for the
changed Services of Arvato by APR prior to the implementation of such change. In such case, Arvato is not obliged to implement any changed or amended processes, arrangements or procedures until the Parties have agreed on the cost impact, if any. In
the event the Parties shall not agree on such changed or amended processes, arrangements or procedures and related cost impact, each Party shall have the right to terminate this Agreement with a prior 12 (twelve) calendar months written notice.

	(4)	 Arvato possesses and shall maintain during the term of this Agreement all licenses and shall continue to meet
all mandatory legal requirements necessary to fulfil its obligations under this Agreement and the Quality Agreement. 

  

	(5)	 Arvato, except in the event of different written agreement between the Parties, shall, (i) use the mean of
transportation initially defined with APR, (ii) arrange the transportation and (iii), if applicable, obtain any export license and other official authorization and carry out all customs formalities necessary for any exportation of the Products
from the Facility to the respective APR’s Customers within the Territory at APR’s cost if required by APR in writing and in accordance with the requirements as set forth in Schedule B. The transport conditions shall be based upon
the specification for the transportation of the Products. 

  

	(6)	 All orders received by Arvato defined in Schedule B shall be ready for dispatch on the same Business
Day. 

  

	(7)	 Arvato shall observe the FE-FO (first expired-first out) principle in
its stock keeping and stock rotation of the Products 

  

	(8)	 Arvato shall be in charge of the handling of returns of Products from Customer to the Facility according to the
process described in Schedule B. 

  

	4.	 Pricing and Terms of Payment 

 

	(1)	 The pricing of the Services is determined in Schedule D and is based upon the assumptions set out
therein and in the original volumes set out in Schedule E. If actual volumes exceeds from the original volumes by 25% or more in each of two consecutive months, then the relevant Services, which exceed 125% of planned value based thereon,
will have to be repriced. The Parties have to negotiate the impact in good faith. All invoices will be in Euro (€). The Parties agree that, for the first calendar year, the term to evaluate eventual differences in the assumptions indicated in
Schedule D and Schedule E, shall be 6 (six) consecutive months. 

  

	(2)	 Invoices for Services provided by Arvato to APR under this Agreement will be generated on a consolidated basis
monthly pursuant to the following scheme: 

  

	 	•	 	 Within the second Business Day of month, Arvato shall anticipate to APR an excel format document with the detail
of the Services rendered to APR for the previous month and to be invoiced; 

  

	 	•	 	 and within the 5th Business Day of the month Arvato shall provide to APR the invoice itemized with each Service
rendered. 

  

	 	•	 	 Payment of Services will be due at 60 (sixty) days net after the invoice date. 

 

	(3)	 If an invoice is not paid at the due date according to Section 4 paragraph 2, then the late payment
interest charges prescribed by 231/02 law shall apply to the invoiced amounts. The right to enforce more extensive compensatory damage claims is reserved. Should APR fail to pay for the invoiced Services at the due date, either in whole or in part
and without having justified its delay in writing, then Arvato shall give the APR a grace period of 5 (five) Business Days from Arvato notice to APR of the unpaid invoice. In the event APR fails to settle the payment within such grace period, Arvato
shall have the right to suspend the Services or to enforce any other right. If at least 2 (two) consecutive months payments are overdue and APR fails to make such payments (including interest), then Arvato will be entitled to terminate this
Agreement pursuant to Section 19. 

	(4)	 The agreed prices do not include any applicable taxes and value added taxes (VAT), if applicable. Any VAT or
equivalent tax such as goods and sales taxes or use and sales taxes, if any, shall be borne by APR and will be added to those prices and shown as a separate line item in all invoices at the prevailing local rate. 

 

	(5)	 Within the end of October of every year the Parties will review the applicable consumer price index established
by ISTAT for Italy for the previous twelve (12) months and apply this change to the pricing in Schedule D for the following calendar year. In addition and limitedly to the transportation prices, Arvato shall have the right to one yearly
review and adjustment, provided that such increase and adjustment shall have to i) absorbed any price index increase; ii) shall be documented by Arvato, if possible, or shall be attested by an official declaration of Arvato in the event Arvato
cannot provide document attesting such increase without violating any confidentiality obligation; iii) not exceeding a limit of 5% (five percent) except in the event of unpredictable event beyond any reasonable control of Arvato and provided that,
any violation of previous points i), ii) or iii) shall be deemed as a material breach that shall entitled APR to terminate the Agreement as per Section 19.5.a. 

 

	5.	 APR’s Obligations 

 

	(1)	 APR represents and warrants that the Products comply with all Applicable Laws, rules and regulations, in
particular with the applicable FSMP regulation as applicable from time to time, and that they meet all demands and standards set by the Regulatory Authorities in the Territory at the time of their delivery and for the time of the shelf life
indicated on the respective packaging, and that the Products conform to APR’s manufacturing specifications, and that the Products are free from deficiencies and defects and shall not constitute a risk for health, life or property of any person
as long as they are properly stored, handled and used. 

  

	(2)	 APR warrants and represents that APR has obtained and throughout the term of this Agreement shall maintain all
permits, licenses and approvals necessary for the import of the Products in the Territory and for the distribution within the Territory. 

  

	(3)	 APR warrants and represents that APR lawfully possesses the due titles and licenses and that the Products, and
shall exert its best effort, throughout the term of this Agreement, in order not to infringe any patents, trademarks or other Intellectual Property of any Third Party. 

 

	(4)	 APR shall defend, indemnify and hold harmless Arvato and/or its Affiliates from and against any claims,
actions, suits, demands and other proceedings, damages costs, and expense, liabilities (including but not limited to attorney’s fees and costs) arising from or out of (i) any breach of APR’s warranties, representations and agreements
set forth in this Section 5 Clauses (1) to (3) above, (ii) the infringement of any patents. trademarks or other intellectual property rights of any Third Party regarding the infringement of design, manufacture, sale, advertisement or
any other use of the Products, and/or (ii) the purchase or use by any Third Party of the Products. 

  

	(5)	 APR shall import and be designated as the importer of record for the Products in the Territory and is
responsible — unless expressly provided otherwise in this Agreement -for insurance cover, especially marine insurance, and documentation in this function of an importer. 

	(6)	 Subject to clause 5.4 APR’s liability for breaches of this Agreement shall be limited to lost profit, loss
of revenue or goodwill. 

  

	6.	 Sub-Contractors 

Arvato shall perform the Services under this Agreement as an independent contractor and is entitled to engage one or more Subcontractors of its
own choice, subject to notice thereof in writing to APR. Similarly, Arvato shall not change any such Subcontractor without notice thereof to APR. If any such Subcontractor is auditable, then Arvato shall provide APR access to all audit reports
generated by or for Arvato with respect to such Subcontractor related to the Services. Arvato shall be liable for any acts, errors or omissions of any Subcontractor. For the purposes of this Agreement, any acts, errors, omissions or breach of any
Subcontractor shall be deemed to be as a breach of Arvato. However, the foregoing provision shall not apply for any acts, errors or omissions of any Carrier (in which case Clause 9 3(3) of this Agreement applies). 

 

	7.	 Storage Area 

  

	(1)	 Arvato will keep the proper storage of the Products under custody to carry out its warehousing and
distribution. The storage area shall comply with Applicable Laws and requirements from Regulatory Authority and shall fulfill APR’s requirements with regard to size, temperature, tidiness and security for the term of this Agreement. Binding
minimum requirements to be fulfilled by Arvato are set out in the Quality Agreement. Particular standards and / or requirements will be separately and in writing agreed upon between the Parties. 

 

	(2)	 In case of the expiration or termination of this Agreement, Arvato will carry out an inventory count of the
Products. Arvato will prepare and make available Products at the ramp of the warehouse for picking-up arranged and paid by APR. 

 

	(3)	 The provision of the Services as set forth in Clause (3) above will be charged to APR on the basis of
Arvato’s price list set forth in Schedule D attached hereto plus any applicable VAT, if any. 

  

	8.	 Property 

The Products shall be collected FCA (Incoterms 2010) by, and under responsibility of, Arvato at the Third Party facility indicated by APR. As
of the Effective Date hereof, the Third Party facility is Labomar s.p.a., via Fabio Filzi, 55 — 31036 Istrana (TV) and transferred to, and then stocked at, Arvato’s Facility unloading bay as described in Schedule B. The stored
Products will remain APR’s sole property and Arvato only takes them under its custody for the purposes stated in this Agreement. APR warrants that Products will be identifiable as APR’s property. Arvato will confirm APR’s ownership of
the stored Products to any Third Party in writing if so reasonably demanded by APR. 
  

	9.	 Freight Management/Shipment of Products 

 

	(1)	 Arvato is responsible for the assignment and organisation of the shipment of the Products to APR’s
Customers (Carrier selection based on the transport concept (cf. Section 3 Clause (5), and Carrier administration incl. invoicing). Arvato concludes the necessary contracts with the Carrier in its own name. Arvato will invoice APR for these
services according to Schedule D (transport pricing). 

	(2)	 APR shall take out a transportation insurance for all shipments organized by Arvato on behalf of APR. APR will
procure a waiver of recourse issued by the respective insurer to the benefit of Arvato that ensures that the insurer will not take recourse vis-a-vis Arvato as follows:

 “The insurance carrier waives its recourse claims (subrogation rights) (and any comparable regulation) for any
damages, to the extent that these were not caused by the gross negligence or intentional acts or omissions of the statutory representatives and/or agents of Arvato Services Italia S.r.I.. The only statutory representatives and/or agents for this
purpose are management board members, managing directors and general partners or the highest representative officers and directors appointed under statutory law.” 

If APR is not able to procure the waiver, APR will provide a suitable alternative for the protection of Arvato from claims by the insurance
company. If APR does not provide a suitable alternative, APR will, upon Arvato’s request, fully indemnify and hold harmless Arvato from and against such claims, provided the damage was not caused by the gross negligence or intentional acts or
omissions of the statutory representatives and / or agents of Arvato. The only statutory representatives and / or agents for this purpose are management board members, managing directors and general partners or the highest representative officers
and directors appointed under statutory law. 
  

	(3)	 For the avoidance of doubt, Arvato’s liability begins with the receipt of the relevant Products at the
moment when Arvato collects the Products at the Third Party Facility and ends upon of the delivery of such Products by the Carrier to the Customer. Arvato’s liability for transport damages — including lost shipments — in connection
with the delivery of the Products to the Customer is disclaimed and excluded, except for mistakes occurring within Arvato’s sphere of responsibility (loading ramp for outgoing Products) or for damages which are based on Arvato’s improper
packing of the Products, unless the Convention on the Contract for the International Carriage of Goods by Road (“CMR”) applies, in which case, Arvato will be liable under the provisions of the CMR. 

 

	(4)	 Starting from the 1st of July 2019 until December 31st, 2019, in the event Arvato shall receive for two
consecutive months at least 100 (one hundred) orders per month from APR’s , a bonus / malus mechanism shall apply on the three most critical KPI’s (as defined in the BRD — Business Requirement Document attached hereby under
Schedule B) according to the following terms (collectively the “Bonus / Malus”): 

  

	 	•	 	 KPI 1—Orders entered correctly in the system: target is above or equal to [***]% as per the BRD
(Schedule B). 

  

	 	•	 	 KPI 2—Damaged Units: target is below or equal to [***]% as per the BRD (Schedule B).

  

	 	•	 	 KPI 3—On Time Delivery—Germany / Italy I CH: target is above or equal to [***]% as per the BRD
(Schedule B). 

 a) In the event the cumulated result for KPI 1, measured on 2 (two) months in a row, will
exceed the value of [***]% a bonus of plus 1 % (one percent) shall apply on the total amount of the following month invoice. Otherwise if the cumulated result for KPI 1, measured on 2 (two) months in a row, will be inferior to the value
of [***]% a malus of minus [***]% ([***]) will apply on the total amount of the following month invoice. 

 b) In the event the result for KPI 2, measured each year, shll be inferior to the
value of [***]% a bonus of plus [***]% ([***]) shall apply on the total amount of the following year invoices. Otherwise if the result for KPI 2, measured each year, will exceed the value of [***]% a malus of minus [***]% ([***]) shall apply
on the total amount of the following year invoices. 
 c) In the event the cumulated result for KPI 3, measured on 2 months in a row,
will be included between the value of [***]% and [***]% a bonus of plus [***]% ([***]) will apply on the total amount of the following month invoice. In the event the cumulated result for KPI 3, measured on 2 months in a row, will exceed the
value of [***]% a bonus of plus [***]% ([***] percent) will apply on the total amount of the following month invoice. Otherwise if the cumulated result for KPI 3, measured on 2 months in a row, will be inferior to the value of [***]% a malus
of minus [***]% ([***]) will apply on the total amount of the following month invoice. 
 Upon January 1st 2020, the Bonus / Malus shall apply independently
from the amount of order collected in a month (for sake of clarity, it shall not be necessary to reach one hundred orders per month in order to apply the Bonus / Malus). 

Arvato shall send to APR a KPI report on a monthly basis which will be used to evaluate the Bonus / Malus. 

 

	10.	 Inventory/Stock Taking 

Stock taking will be carried out once a year as an annual inventory count. The results will be passed on to APR. Preparation and realisation
will be mutually agreed upon in writing. Arvato will follow the respective requirements defined in the Quality Agreement. Notwithstanding the aforesaid, Arvato will ensure that APR is provided electronically on a daily basis with any inventory
information necessary to track the Products. 
 Additional stock takings during the year shall be carried out only upon request of APR and on
the base of costs previously agreed by the Parties. 
  

	11.	 Liability/Indemnification 

 

	(1)	 Arvato will be liable for all claims for damages, costs, etc. arising out of or in connection with the
Agreement, its Schedules and Exhibits, Appendices and Amendments that are caused of by either Arvato’s or any of its Subcontractors’ at least negligent acts or omissions, upon the following terms: 

 

	(2)	 With respect to storage and distribution (logistics services) Arvato’s liability begins with the
collection of the respective Products at the Third Party facility unloading ramp and ends with the delivery of the Products to the Customer (Sec. 9 Clause (3)). 

 

	(3)	 Subject to following clause (8), Arvato’s liability (including indemnifications) to APR for any and all
claims of all claimants whatsoever of any kind and nature arising in a contractual year out of or in connection with this Agreement, its Schedules and Exhibits, Appendices and Amendments including the Quality Agreement shall be limited to an
aggregate in any contractual year limited by EUR 200.000 per year. 

  

	(4)	 Subject to following clause (8), in no event shall Arvato be liable for any indirect or consequential damages
or lost profit, loss of revenue or goodwill, whereby the indemnity claim will also include the costs of any judicial and/or extra-judicial legal enforcement/defense. 

	(5)	 With respect to all remediable defects or deficiencies each Party shall notify the other in writing without
undue delay of a recognized or recognizable defect or deficiency for Product handled or to be handled by Arvato. Provided that the respective cure period for a remediable breach has lapsed and the respective breach has not been cured, then APR shall
be entitled to claim damages within the limitations set forth in this Section 11. 

  

	(6)	 Notwithstanding the foregoing clause (5), in the event APR submits any information or material that does not
conform to Arvato’s specifications as set in the Schedule B (Business Requirements Document) and Quality Agreement or otherwise does not meet the requirements set by Arvato, Arvato liability for claimed defects, deficiencies, damages or
other losses arising as a result thereof shall be excluded for as long as such claimed defect or damages are direct consequence of the omissions or defects from APR. 

 

	(7)	 Arvato’s liability shall be excluded in case Arvato has acted in accordance with APR’s written
instructions or specifications pursuant to this Agreement and APR shall hold harmless Arvato against any Third Parties’ claims or losses arising out of such instructions or specifications. 

 

	(8)	 Under no circumstances shall any of the above limitations in clauses (1) through (7) be construed as
limiting the liability of Arvato in respect of any claim raised as a result of fraud, intent. wilful misconduct or gross negligence. or in respect of death or personal injury caused by the relevant Party’s negligence or any other liability
which cannot, under Applicable Law, be limited or excluded. 

  

	(9)	 If and to the extent that a Party’s liability is disclaimed and excluded under the aforementioned
provisions. the other Party shall indemnify such Party with respect to all Third Party claims, whereby the indemnity claim will also include the costs of any judicial and/or extra-judicial legal enforcement/defense. Settlements and acknowledgements
under this indemnity obligation are subject to the written consent of the Party that has to be maintained harmless. 

  

	(10)	 If and to the extent Arvato is liable to APR according to this Section 11, Arvato shall indemnify and hold
APR harmless. Notwithstanding the foregoing, Arvato shall not be liable under this Section 11, if APR: 

  

	 	(i)	 fails to give Arvato written notice of any such claim within the terms settled by the Applicable Law;

  

	 	(ii)	 fails to allow Arvato the right to participate in the defence and settlement of the claim as a participant, as
long as Arvato has formally requested to participate; 

  

	 	(iii)	 fails to give Arvato all reasonably requested assistance in the defence or settlement of the claim (at Arvato
expenses); or 

  

	 	(iv)	 enters into any settlement or compromise of the claim without the Arvato’s prior written consent (that
shall not unreasonably withheld), 

 provided, however, that 

 

	 	(a)	 clauses (ii) through (iv) shall only apply after Arvato has acknowledged its obligation to indemnify APR
against such claim, should the defence not be successful, to APR in writing, and 

	 	(b)	 the exclusion from liability set forth in clauses (i) through (iv) would only apply if Arvato’s
ability to defend itself or limit its liability hereunder has been materially impaired or damaged by APR’s failure to fulfil the conditions set forth in clauses (i) through (iv). 

 

	12.	 Insurance 

  

	(1)	 Without limiting Arvato responsibilities under previous Section 11, subejct to Section 5 Clause
(5) and Section 9 Clause (2), Arvato shall throughout the term of this Agreement take out and maintain a commercial general liability insurance with limits of EUR 1.000.000 per occurrence (two times annual aggregate) covering bodily injury
and property damage. Arvato shall on APR’s written request provide written evidence of such policy (insurance certificate) as soon as practicable after the Effective Date. 

 

	(2)	 APR will take out at its own cost and discretion insurance for the Products stored and handled by Arvato and
for inbound shipments of the Products to Arvato and for shipments of the Products to a Customer, in each case arranged by Arvato in accordance with the terms and conditions of this Agreement (property and freight insurance ). For that cause APR
shall procure that a waiver of recourse will be provided by the insurer to the benefit of Arvato that ensures that the insurer will not take recourse vis-a-vis Arvato;
Section 9 Clause (2) Sentence 2 et seqq. shall apply accordingly. 

  

	13.	 Force Majeure 

 

	(1)	 Each Party shall not be liable to the other Party for damage or loss, for delays or for failure to perform
occasioned by Force Majeure, such as national strikes, riots, lockouts, civil commotion, terrorist act, labour disputes, fires, floods, earthquakes, explosions, failure of communication facilities or other causes beyond their reasonable control and
not caused by its own negligence. Each Party agrees to promptly notify the other Party as soon as it becomes aware of any such Force Majeure event has occurred that is likely to cause its non-performance or
delay. 

  

	(2)	 In the event the Force Majeure event affects Arvato, the period for delivering the Services will be extended by
the duration of the hindrance due to such Force Majeure event. If the aforementioned circumstances should render the delivery of the Services impossible or unreasonable, then Arvato shall be relieved of such duties. 

 

	(3)	 In the event the Force Majeure event affects Arvato, if Force Majeure persists for a period longer than eight
(8) weeks, APR is entitled to either resort to another service provider for the Services in the relevant Territory (in which case the exclusivity pursuant to Section 2 Clauses (3) will no longer apply for that Territory during such
period), or terminate this Agreement with immediate effect. 

  

	14.	 Confidentiality 

 

	(1)	 Each Party undertakes that it (whether by its officers, servants, agents or otherwise howsoever) will not
during the term of this Agreement, save by compulsion of law, use, publish. disclose to any Third Party or cause to be so used, published or disclosed save in accordance with the terms hereof any Confidential Information. 

 

	(2)	 Each Party further undertakes to use its best endeavours to ensure that such Confidential Information is kept
secure and to prevent any unauthorized use, publication or disclosure of such information by any of its employees. 

	(3)	 Each Party shall impose written duties of confidentiality upon its other potential contracting parties, who
contribute in the performance of the Services under this Agreement. 

  

	(4)	 Each Party undertakes to impose a written obligation of confidentiality on all of its staff members and on all
other persons being commissioned by it with the execution of this Agreement, each to the extent they are not already bound to maintain confidentiality otherwise (e.g. by their existing employment agreements). 

 

	(5)	 Each Party may disclose Confidential Information: 

 

	 	(i)	 if and to the extent required by applicable laws or for the purpose of any judicial proceedings or arbitration;

  

	 	(ii)	 if and to the extent required by any authority to which that Party is subject, wherever situated;

  

	 	(iii)	 to its holding company, its Affiliates, its legal advisers and auditors; 

 

	 	(iv)	 if and to the extent the information has come into the public domain through no fault of that Party; or

  

	 	(v)	 if and to the extent the other Party has given prior written consent to the disclosure. 

 

	(6)	 The obligations resulting from this Section 14 shall remain unaffected and continue for a period of two
(2) years after expiration or termination of this Agreement for any reason whatsoever. 

  

	(7)	 Without prejudice to Section 14 Clause (5), each Party will, at the appropriate written request from the
other Party, return all documents and data carriers which were received from the other and which contain Confidential Information of such Disclosing Party. Each Party acknowledges that Confidential Information might be automatically copied through
backup standard procedures. In case that the destruction or return of such Confidential Information is not possible with reasonable efforts, the receiving Party shall be entitled to keep such Confidential Information confidential under the terms and
conditions of this Section and shall not be entitled to use such Confidential Information. 

  

	15.	 Data Protection 

 

	(1)	 In performing the provisions of this Agreement, each Party agrees to comply with applicable data protection
law. 

  

	(2)	 The Parties will enter into a corresponding agreement on data protection and on data security in connection
with the processing of personal data in accordance with Regulation GDPR no. 679/16 and following amendments. 

  

	16.	 Information and Regulatory Assistance 

Arvato shall cooperate with APR and shall, at its sole, but fair discretion, produce any documents or other information which APR necessarily needs in order to
meet APR’s statutory and regulatory requirements. Particularly, and without limiting the generality of the foregoing, Arvato will provide APR with any information which APR needs to make the necessary notifications and applications under the
German Medicinal Drugs Act or FSMP legislation as applicable to the Products. 

	17.	 Exclusion of Transfer of Personnel 

 

	(1)	 The Parties jointly assume that the fulfillment of the business requirements by Arvato under the authority of
the APR does not constitute any form of partnership, association or corporate agreement, nor it may be deemed as a transfer of business undertaking (“trasferimento di azienda/ramo d’azienda”) operation within the meaning
according to Article 2112 of the Italian Civil Code or similar foreign provisions (including EU Directive 77/187/EEC and legislation which was enacted on the basis of that Directive) from the APR or contracting parties of the APR to Arvato and that
for this reason, no employment contracts with employees of the APR or with employees of the contracting parties of the APR shall pass to Arvato in connection with the conclusion or performance of this Agreement. 

 

	(2)	 If, in connection with concluding or performing this Agreement, the employees of APR assert that their
employment contract has passed to Arvato or raise claims against Arvato in connection with the alleged transfer of their employment contract, then APR agrees to support Arvato in defending against the claims and shall indemnify Arvato from any and
all claims and costs arising in connection with the transfer of the employment contracts. These costs include, inter alia, costs related to salary, health insurance, social security taxes, voluntary or statutory pension contributions, company
retirement programs, a reasonable comparable severance package and/or severance payments, which are based on legislation, a collective bargaining agreement, or a judicial or administrative decision, compensatory damage payments or similar payments
which are owed to the relevant employee based on an unjustified termination or dismissal. 

  

	(3)	 If, in connection with concluding or performing this Agreement, the employees of Arvato or employees of the
Subcontractors of Arvato assert that their employment contract has passed to APR or raise claims against APR in connection with the alleged transfer of their employment contract, then Arvato agrees to support APR in defending against the claims and
shall indemnify APR from any and all claims and costs arising in connection with the transfer of the employment contracts. These costs include, inter alia, costs related to salary, health insurance, social security taxes, voluntary or statutory
pension contributions, company retirement programs, a reasonable comparable severance package and/or severance payments, which are based on legislation, a collective bargaining agreement, or a judicial or administrative decision, compensatory damage
payments or similar payments which are owed to the relevant employee based on an unjustified termination or dismissal. 

  

	18.	 Intellectual Property Rights, Rights of Use 

 

	(1)	 Arvato acts only as a service provider as detailed under Section 2 Clause (3) according to the terms
and conditions of this Agreement. APR and/or its licensors or Affiliates shall remain the owner of all of the APR Intellectual Property. Arvato and/or its licensors or Affiliates shall remain the owner of all of the Arvato Intellectual Property. No
license, either expressed or implied, is granted to Arvato under any trademark owned or controlled by APR for any of the Products, except that Arvato may use the trademarks for APR Products only for the purposes of performing its obligations under
this Agreement. 

  

	(2)	 Arvato shall take no steps, directly or indirectly, to attempt to secure any rights (including the filing of
any applications for registration or obtaining any registrations) in any of the trademarks used on or in connection with the APR Products. 

	(3)	 Arvato shall not, during the term of this Agreement or thereafter, market, directly or indirectly, any product
under any trademark which is the same as or similar to that used on any of the APR Products, or which so closely resembles the same that it would be likely to lead to confusion or uncertainty or to otherwise deceive or mislead the public.

  

	(4)	 Upon termination or expiration of this Agreement for any reason whatsoever, Arvato shall not, directly or
indirectly, thereafter use or attempt to register any trademark which is the same as or similar to any trademark used on any of the Products, or which so closely resembles the same that it would be likely to lead to confusion or uncertainty or to
otherwise deceive or mislead the public. 

  

	(5)	 Arvato shall immediately inform APR of any improper or wrongful use of which Arvato becomes aware in the
Territory in which the Products are distributed. 

  

	(6)	 Arvato retains the exclusive, perpetual right to use any software solutions, which it deploys for purposes of
performing this Agreement, even if—as part of the cooperation under this Agreement—it is requested to developed and/or adjusted such solutions and is paid by the APR to do so. Otherwise, Arvato remains the sole owner of the software used
in performing the contract and the IT hardware, also to the extent that it had procured and/or developed and/or adjusted it under this Agreement. 

  

	19.	 Term and Termination 

 

	(1)	 This Agreement, the Quality Agreement and all related Schedules, Exhibits, Amendments and Annexes attached
hereto shall come into force on the Effective Date. It shall have a term of five (5) years commencing on the Effective Date or on the date APR has obtained all necessary regulatory licenses and has informed Arvato accordingly whichever occurred
later (the “Term”). 

  

	(2)	 In case of significant deviations from the assumed volumes documented in Schedule E (“Original
Volumes”), at the end of the first 28 (twenty-eight) calendar months from the Effective Date, the Parties will have the possibility to negotiate in good faith a modification of the Agreement. In the event the Parties shall not reach an
agreement within March 1st, 2021, each Party can terminate this Agreement with a prior written notice of 10 (ten) calendar months. 

The Parties therefore acknowledge that, for the purpose of this Agreement, a significant deviation shall be deemed as follows: 

 

	 	•	 	 The volumes decreasing threshold for APR is 70% of the Original Volumes (Sales Packs + Sample Packs) in the year
2020 evaluated at December 31’, 2020. 

  

	 	•	 	 The volumes decreasing threshold for Arvato is 50% of Original Volumes (Sales Packs + Sample Packs) in the year
2020 evaluated at December 31”, 2020. 

  

	(3)	 The right to terminate the Agreement for convenience shall be excluded for both Parties during the Term.

	(4)	 The right to terminate for cause with immediate effect shall remain unaffected. Either Party (the
“Initiating Party”) may in particular terminate this Agreement by written notice to the other Party (the “Breaching Party”) at any time on or after any of the following events occurred in relation to the Breaching Party:

  

	 	(a)	 the Breaching Party commits a material breach of the terms and conditions of this Agreement and (if such a
breach be remediable) fails to remedy the same within thirty (30) days of receipt of a written notice from the Initiating Party requiring it to do so. For the sake of clarity, the Initiating Party’s right to terminate is subject to
(i) the Initiating Party escalating the subject matter as set forth in Section 233.1 of this Agreement, and (ii) the dispute resolution process having not reached a solution within thirty (30) Business Days;

 ; or 
  

	 	(b)	 the appointment of an administrator of or, the making of an administration order in relation to the Breaching
Party or the appointment of a receiver or an administrative receiver of, or an encumbrancer taking possession of or securing the whole or part of the Breaching Party’s undertaking, assets, rights or revenue. 

 

	(5)	 Without limiting the rights of APR under previous Clause (4) (Arvato’s Services and Obligations), APR may
terminate the Agreement by written notice to Arvato at any time: 

  

	 	(a)	 in the case of Section 13 Clause (3) of this Agreement; 

 

	 	(b)	 In the event Arvato performance in relation to the Bonus / Malus described under Section 9.4 fail for
three consecutive months (for sake of clarity, APR can terminate the Agreement in any case KPI 1 is inferior to 88% for three consecutive months, or KPI 2 is superior to 0.12% for three consecutive months, or KPI 3 is inferior to 80% for three
consecutive months). 

  

	(6)	 Without limiting the rights of Arvato under Clause (4), Arvato may terminate the Agreement by written notice to
the APR as set forth in Section 4 Clause (3). 

  

	(7)	 In the event of a termination of this Agreement, the Quality Agreement shall automatically terminate upon
completion of any unfinished Services placed prior to termination notice and vice versa. 

  

	20.	 Public Relations and References 

As a reference and in order to promote itself, under previous written approval by APR that shall not be unreasonable withheld, Arvato is
granted the right to use/publicize the Services, which must be and/or were provided to APR, while indicating APR’s company name and using the APR’s logo. The Parties shall provide each other with appropriate and approved marketing material
(logos, photos, customer testimonials, etc.). This applies above all to any mention in the press and public relations work of Arvato, any designations in external and internal appearances Arvato such as on websites, as a case study in lectures inter
alia at trade fairs, conventions, graduate school courses, etc., any mentioning in corporate presentations and description of specifically rendered services, and press release publications regarding the contractual relationship between APR and
Arvato. 
 As a reference and in order to promote its products and services, under previous written approval by Arvato (that shall not be
unreasonable withheld), APR is granted the right to use/publicize Arvato as its partner, indicating Arvato’s company name and using the Arvato’s logo. The Parties shall provide each other with appropriate and approved marketing material
(logos, photos, customer testimonials, etc.). This applies above all to any mention in the press and public relations work of APR, any designations in external and internal appearances APR such as on websites, as a case study in lectures inter alia
at trade fairs, conventions, graduate school courses, etc., any mentioning in corporate presentations and description of specifically rendered services, and press release publications regarding the contractual relationship between APR and Arvato.

	21.	 Export Control 

 

	(1)	 The export of certain Products, information, software and documentation may require an export permit —
e.g. based on the nature or use or final location of such items. APR ensures that it has all the necessary permits and that it will maintain them during the term of this Agreement. 

 

	(2)	 APR guarantees that all Products, goods, information, software and documentation, which are subject to a permit
requirement pursuant to EU export lists, are labeled in accordance with the applicable laws, ordinances and regulations. 

  

	22.	 Bertelsmann Code of Conduct 

Arvato explicitly refers to the code of conduct applicable within the Bertelsmann organisation. which can be viewed here: vvww.bertelsmann.de.
Arvato expects its business partners to support Arvato in ensuring compliance with the regulations and principles stipulated therein, and particularly expects support in implementing the principles set out by the United Nation’s Global Compact
Initiative concerning human rights, labour relationships, the environment and anti-corruption (www.uncilobalcompact.orq). 
  

	23.	 Dispute Resolution 

 

	(1)	 In the event of any dispute between APR and Arvato arising out or in connection with the Services or this
Agreement, APR and Arvato shall each use reasonable endeavours to resolve such dispute by means of prompt bona fide discussion at a managerial level appropriate to the dispute in question. Either Party may initiate discussion by written notice to
the other identifying the nature of the dispute and referring to this Section 23. The Parties shall meet within ten (10) Business Days after receipt by the recipient of the notice. If the Parties have not resolved the dispute within 20
(twenty) Business Days of the date of the notice the discussion shall be submit to the Chief Executive Officer of APR and the Chief Executive Officer/Managing Director of Arvato (collectively, the “Executives”), or their respective
designated representative who shall be a senior executive officer with authority to settle the applicable issue or dispute, for resolution. The Executives to whom any dispute is submitted shall attempt to resolve the dispute through good faith
negotiations over a reasonable period, not to exceed 20 (twenty) calendar days, unless the Executives mutually agree in writing to extend such period of negotiation. Such 20 (twenty) calendar days period shall be deemed to commence on the date the
dispute was submitted to the Executives. If the Executives are unable to resolve the dispute within 20 (twenty) calendar days then the Parties may submit the dispute to the competent Court according to following Section 24 (6). All negotiations
pursuant to this Section shall be confidential, and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. 

  

	(2)	 Save as Clause (3) below, neither Party may commence any court proceedings in relation to any dispute
arising out of or in connection with this Agreement until they have attempted to settle it by discussions and such discussions has been terminated. 

  

	(3)	 Nothing in this Section 23 shall prevent either Party from seeking injunctive relief or other interim
relief (including any breach of this Section 23) by the other Party. 

	24.	 Miscellaneous 

 

	(1)	 This Agreement and its appendices form the entire Agreement between the Parties relating to the subject matter
thereof and supersedes and replaces all prior communications, written and oral, between the Parties on its subject matter. 

  

	(2)	 Variations and addendums to this Agreement shall only be valid if made in writing and signed on behalf of each
Party hereto. The same applies to the abrogation and modification of this obligation. 

  

	(3)	 The assignment of individual rights or the delegation of individual duties under this Agreement or the
assignment of the Agreement in its entirety including all rights and duties on the part of Arvato to Bertelsmann SE & Co. KGaA, Gijtersloh, and/or Affiliates of Bertelsmann SE & Co. KGaA is permissible without the consent of the
Customer. 

  

	(4)	 Should any provision of this Agreement or a provision of its annexes be or later become invalid or
unenforceable, either in whole or in part, then the validity and enforceability of the remaining provisions thereof will not be affected thereby. The Parties agree — to the extent legally permissible — to replace the invalid and/or
unenforceable provision with another reasonable valid and enforceable provision which most closely reflects that which the Parties had intended or would have intended, if they had recognized the invalidity and/or unenforceability of the provision in
question. The foregoing also applies if the invalidity of a provision is based on a scale or degree of performance. In that case, the degree or scope of performance, which is legally permissible and which most closely reflects the Parties’
original intent, will be deemed to have been agreed. The same applies analogously, if and to the extent that the Agreement or annexes contains a gap or omission; such gaps or omissions should be filled by a provision. which reflects that which the
Parties had intended or would have intended, if they had recognized that the Agreement or annexes contained an omission or a gap. 

  

	(5)	 It is mutually agreed that the construction, effect and validity of this Agreement and any claims and disputes
arising hereunder or in connection herewith shall be governed in all respects by the laws of Italy under exclusion of the principles on the conflict of laws The UN-Convention on the Sale of Goods shall not
apply. 

  

	(6)	 Any controversy, dispute or claim arising out of or relating to this Agreement shall be exclusively settled
before the courts of Milan (Italy). 

  

	(7)	 All notices required by this Agreement to be given by either Party to the other Party shall be sent by mail or
by facsimile and shall be addressed to the address set forth at the top of this Agreement, which address may be changed in writing by the Party. 

  

	(8)	 This Agreement may be executed in counterparts and in English. 

 In witness hereof, the Parties hereto have caused this Agreement to be executed in two initialed copies by
their duly authorized representatives as of the Effective Date. 
 APR Applied Pharma Research s.a. 

 

									
	BY:	 	/s/ Paolo Galfetti	 		 	BY:	 	/s/ Aldovini Roberto
	Name:	 	Paolo Galfetti	 		 	Name:	 	Aldovini Roberto
	Title:	 	CEO	 		 	Title:	 	Legal Counsel
	Date:	 	Nov. 14, 2018	 		 	Date:	 	Nov. 14, 2018

 Arvato Services Italia S.R.L. 
  

									
					
	BY:	 	/s/ Antonio Amati	 		 	BY:	 	/s/ Martin Zöckler
	Name:	 	Antonio Amati	 		 	Name:	 	Martin Zöckler
	Title:	 	CEO	 		 	Title:	 	Business Director
	Date:	 	31/x/2018	 		 	Date:	 	31/10/2018

 Appendix 
  

							
	Table of Contents	  			
			
	 Schedule A:
	  	RFP Document	  	 	24	 
			
	 Schedule B:
	  	BRD	  	 	25	 
			
	 Schedule C:
	  	FRD	  	 	26	 
			
	 Schedule D:
	  	Pricing and Assumptions	  	 	27	 
			
	 Schedule E:
	  	Original Volumes	  	 	29	 
			
	 Schedule F:
	  	Arvato Subcontractors	  	 	30	 
			
	 Exhibit 1:
	  	Quality Agreement	  	 	31	 
			
	 Exhibit 2:
	  	GDPR – Appointment of Arvato as external data processor	  	 	32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]